Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children

BACKGROUND: A blood-stage vaccine targeting the erythrocytic-stages of the malaria parasite Plasmodium falciparum could play a role to protect against clinical disease. Antibodies against the P. falciparum serine repeat antigen 5 (SE47 and SE36 domains) correlate well with the absence of clinical sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Bougouma, Edith Christiane, Palacpac, Nirianne Marie Q., Tiono, Alfred B., Nebie, Issa, Ouédraogo, Alphonse, Houard, Sophie, Yagi, Masanori, Coulibaly, Sam Aboubacar, Diarra, Amidou, Tougan, Takahiro, Ouedraogo, Amidou Z., Soulama, Issiaka, Arisue, Nobuko, Yaro, Jean Baptiste, D’Alessio, Flavia, Leroy, Odile, Cousens, Simon, Horii, Toshihiro, Sirima, Sodiomon B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471861/
https://www.ncbi.nlm.nih.gov/pubmed/36119062
http://dx.doi.org/10.3389/fimmu.2022.978591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471861/
https://www.ncbi.nlm.nih.gov/pubmed/36119062
http://dx.doi.org/10.3389/fimmu.2022.978591

Ejemplares similares